Toni Choueiri, MD· @DrChoueiri · X·· 2 days agoScore90
Body · original
Negative Ph.III KEYNOTE-866 by #DrJensBedke: perioperative pembrolizumab + neoadjuvant Gem/Cis vs placebo + Gem/Cis in cis-eligible MIBC.
EFS HR 0.88 (95% CI 0.71-1.10), p=0.137.
pCR 44.4% vs 35.8%; OS HR 1.00.
Higher pCR did not translate into EFS benefit.
#ESMO26 #BladderCancer @myESMO @OncoAlert
1026 views · 20 likes · 11 reposts · 0 replies
Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgSource: Toni Choueiri, MD · x.com